Cholesterol lowering in patients with CHD and metabolic syndrome

Lancet

Volumn 369, Issue 9555, 2007, Pages 27-

  Butler, Rob ^a   Wainwright, James ^b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; SIMVASTATIN;

CORONARY RISK; DRUG COST; DRUG MEGADOSE; DRUG OVERDOSE; HEART INFARCTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LOW DRUG DOSE; MEDICAL AUDIT; METABOLIC SYNDROME X; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION;

EID: 33845892767     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60025-7     Document Type: Letter

References (5)

1. Deedwania P., Barter P., Carmena R., et al., for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
2. Cannon C., Braunwald E., McCabe C., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
3. Schwartz G., Olsson A., Ezekowitz M., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
4. Nissen S., Tuzcu E., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
5. Nissen S., Nicholls S., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565